Candepres

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Candepres

Candepres: What is This Medicine?

Property Description
Active ingredient Candesartan cilexetil (Prodrug)
Form Oral tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
General purpose Cardiovascular support
Origin Synthetic compound

Classification and Core Composition

Candepres is defined as a systemic, synthetic pharmaceutical agent delivered as a single-agent oral tablet, clinically recognized for its role in supporting cardiovascular function. Its composition centers on the active ingredient, Candesartan cilexetil, which serves as an inactive prodrug that is fully converted into the active therapeutic entity, Candesartan, upon absorption. The medicine is officially classified as an Angiotensin II Receptor Blocker (ARB), often referred to as an Angiotensin II Type 1 Receptor Antagonist. This classification places it within the established therapeutic class of antihypertensive agents. Unlike some related sartans, Candepres is a monotherapy product, focusing solely on the mechanism provided by Candesartan cilexetil, providing a clear profile for individuals requiring single-agent oral antihypertensive therapy.

Mechanism and General Purpose

The general function of Candepres involves selectively blocking the AT1 receptor, thereby inhibiting the natural vasoconstrictor effects of Angiotensin II throughout the cardiovascular system. This antagonism is consistent and sustained in nature. This mechanism reduces vascular resistance by promoting the relaxation and widening of blood vessels. This action is designed to facilitate smoother blood flow through the circulatory system, providing sustained support for heart and vessel function. The medicine’s core general purpose is contributing to stable cardiovascular health.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Candepres?

Possible Side Effects and Safety Information

This section details the officially documented adverse reactions and safety constraints for Candepres (Candesartan cilexetil), based solely on regulatory information.

Official Adverse Reaction Profile

Adverse effects are documented and classified by frequency and by System-Organ Class (SOC), covering systems such as the nervous system, respiratory tract, and renal/urinary system.

Frequency Classification Examples of Adverse Reactions (SOC)
Common Upper respiratory tract infection, Dizziness, Headache
Very Rare Hyperkalaemia (high potassium), Angioedema, Renal impairment/failure, Leukopenia
Not Known Diarrhoea, Intestinal angioedema

Serious Warnings and Safety Constraints

Boxed Warning: The regulatory label includes a prominent warning for Fetal Toxicity. Candepres is contraindicated during the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus. Use in children under 1 year of age is also contraindicated for the treatment of hypertension.

Clinically Significant Reactions: Serious reactions include symptomatic hypotension (low blood pressure), especially in heart failure patients or those who are volume-depleted, and deterioration of renal function. There is an increased risk of hyperkalemia (high potassium levels), which is monitored during dose changes and in susceptible patients.

Contraindications & Cautions: Candepres is contraindicated in cases of known hypersensitivity, during later stages of pregnancy, and in patients with severe hepatic impairment or cholestasis. Caution is advised regarding co-administration with other agents that block the Renin-Angiotensin System (RAS) due to heightened risks of hyperkalemia and renal issues.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Candepres (Candesartan cilexetil) is expected to primarily affect the cardiovascular system, leading to consequences related to its blood pressure-lowering effect. The overall clinical profile is defined by the manifestation of severe hypotension.

Signs and Expected Manifestations

Based on official regulatory documentation, the two main expected clinical presentations of overdosage are:

  • Symptomatic Hypotension: A severe drop in blood pressure accompanied by related symptoms.
  • Dizziness: A common manifestation resulting from the physiological effect of low blood pressure.

While high single doses up to 672 mg have been documented without permanent harm in one case, the potential for severe hypotension is the critical complication. Regulatory data states that no serious adverse events were reported in premarketing clinical trials due to overdosage.

Required Emergency Actions

Immediate medical attention is necessary if any signs of overdosage or symptomatic hypotension occur. Regulatory authorities mandate the following actions for management:

  1. Contact your Regional Poison Control Center immediately for specific guidance.
  2. If symptomatic hypotension develops, supportive treatment must be instituted. This intervention requires close medical supervision and the administration of intravenous fluids.

It is officially noted that the active component, Candesartan, cannot be removed from the bloodstream using hemodialysis.

Therapeutic Uses of Candepres

What Candepres Treats: Main Uses and Benefits

Candepres is commonly used in clinical settings that involve heightened systemic burden, primarily to help manage chronic cardiovascular conditions. The medication is applied across therapeutic domains for Essential Hypertension and Chronic Heart Failure.

The primary therapeutic benefit generally supports long-term risk reduction and symptom support. It assists with maintaining functional stability by managing the persistent strain of high blood pressure and contributes to easing the overall symptom load associated with heart weakness, such as congestion and shortness of breath.

“This therapy is applied when supportive symptom management is appropriate, assisting with maintaining functional stability when symptoms become more noticeable.”


Quick Fact: Relief for Systemic Strain

Quick Fact: Relief for Systemic Strain Candepres is considered relevant for easing the impact of symptoms linked to organ-specific functional stress, providing supportive relief when high pressure interferes with routine activities and general well-being.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Candepres

The following rules reflect the official population eligibility and non-eligibility criteria for Candepres (Candesartan cilexetil) as documented in regulatory labeling.

Contraindicated Populations

Use is contraindicated for patients with known hypersensitivity to the medicine, severe hepatic impairment or cholestasis, and children aged below 1 year. The medicine must also not be used during the second and third trimesters of pregnancy, or concomitantly with aliskiren-containing products in patients with diabetes or moderate-to-severe renal impairment.

Age and Organ Function Rules

Category Official Regulatory Statement
Age-Related Eligibility Approved for adults and children aged 1 to < 18 years for hypertension. Use for heart failure is not established in the pediatric population.
Condition-Specific Rules Restricted use applies to patients with renal or mild-to-moderate hepatic impairment, requiring special medical consideration. Use in patients with severe renal impairment (CrCl < 15 ml/minute) is associated with limited experience.
Pregnancy and Lactation Not recommended during the first trimester of pregnancy or for nursing mothers.

The official eligibility profile is structured by these absolute prohibitions and conditional constraints. Use is permitted only for established indications in eligible age groups, and restrictions govern use in patients with compromised organ function or specific comorbidities, ensuring adherence to mandated regulatory boundaries.

What should I know about interactions with other medicines?

Candepres, which contains the active substance candesartan cilexetil, may interact with several other medicines primarily through pharmacodynamic effects related to its action on the renin-angiotensin-aldosterone system.

Interacting Medicinal Product Categories

Category Interaction Type Required Action
Potassium-Sparing Agents (e.g., spironolactone, amiloride), Potassium Supplements, Salt Substitutes Increased serum potassium levels (hyperkalemia). Close monitoring of serum potassium is essential.
Lithium-Containing Products Increased serum lithium concentrations and toxicity. Careful and regular monitoring of lithium levels is recommended.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors and high-dose aspirin Decreased blood pressure-lowering effect; increased risk of worsening kidney function, especially in dehydrated or elderly patients. Increased monitoring of kidney function and hydration status is advised.
Other Antihypertensive Medicines (e.g., ACE inhibitors, aliskiren) Increased risk of adverse effects, including low blood pressure, high potassium, and worsening kidney function. Do not combine with aliskiren in patients with diabetes or kidney impairment. Dual blockade of the RAAS is generally not recommended and requires close, specialized monitoring if deemed essential.

Other Relevant Interaction Conditions

  • Anesthetics: If undergoing surgery, inform healthcare professionals about Candepres use, as it may cause a significant drop in blood pressure with certain anesthetics.
  • Alcohol: Consumption of alcohol may increase the risk of dizziness or fainting due to additive blood pressure-lowering effects.

Mechanism of Action

Selective Blocking of the AT1 Receptor

Candepres's active molecule, candesartan, functions as a selective competitive antagonist of the Angiotensin II type 1 (AT1) receptor. This receptor is distributed across vascular smooth muscle, adrenal glands, and kidneys. The drug binds to this receptor, suppressing the signals typically mediated by Angiotensin II and initiating a cascade that influences the determinants of systemic pressure.

Modulating the Renin-Angiotensin-Aldosterone System (RAAS) Cascade

Receptor blockade disrupts the full systemic RAAS cascade by reducing the downstream release of aldosterone from the adrenal glands. This influences multiple bodily systems, leading to an adjustment of both vascular tone and fluid/electrolyte balance through reduced sodium and water reabsorption.

Influencing Tissue Signaling

Beyond hemodynamic effects, the chronic inhibition of the AT1 receptor influences cellular and tissue-level processes. This mechanism mitigates the profibrotic and pro-hypertrophic signaling that drives structural changes, thereby influencing the structural integrity of the heart and blood vessels.

Dosage and Administration Information

Candepres (candesartan cilexetil) is administered exclusively via the oral route using tablets available in strengths of 4 mg, 8 mg, 16 mg, and 32 mg. The medication is designed for once-daily intake and can be taken with or without food.

For Essential Hypertension, treatment typically begins with a dose of 16 mg once daily. The maintenance dosage generally ranges from 8 mg to 32 mg, not to exceed the maximum recommended dose of 32 mg per day. For Chronic Heart Failure, the initiation dose is 4 mg once daily. The protocol aims for a maximum dose of 32 mg daily, achieved through a process of titration where the dose is approximately doubled at intervals of at least two weeks.

Specific considerations for patient populations apply to this medication. In patients with severe renal impairment or moderate hepatic impairment, a lower starting dose (such as 4 mg or 8 mg) is generally considered to reflect the drug’s processing characteristics. However, older adults typically do not require an initial dosage adjustment based on age alone. For patients unable to swallow the tablets, the tablets may be crushed and used to prepare an extemporaneous oral suspension.

Recent Clinical Evidence

Evidence for Use in Essential Hypertension

The research base for Candepres in high blood pressure was evaluated through double-blind, randomized controlled trials (RCTs). These studies included adults with mild to moderate hypertension, as well as specific cohorts like older adults and pediatric patients aged 1 year and older. The primary outcomes monitored were changes in trough sitting Systolic and Diastolic Blood Pressure (SBP and DBP) over short-term periods (typically 4 to 12 weeks). Comparative research examined blood pressure measurements across a 24-hour cycle. Long-term major event data largely derive from pooled analyses rather than dedicated primary studies.


Evidence for Use in Chronic Heart Failure

The research base in chronic heart failure (CHF) studies explored long-term patterns through large-scale, event-driven RCT programs, such as CHARM. These trials monitored outcomes in adult patients with symptomatic heart failure, including those with reduced and preserved ejection fraction. The primary outcomes explored the time to an event such as cardiovascular death or hospitalization for a worsening heart failure episode. Findings for cardiovascular death in the preserved heart function (HFpEF) group remain heterogeneous.


Long-Term Studies and Durability of Response

The research base contains long-term follow-up from trials that studied chronic heart failure, monitoring patient outcomes over several years. However, long-term outcomes are not fully established across all studied conditions, and follow-up durations were limited in the initial shorter hypertension studies.


Evidence in Special Populations

Research explored the use of Candepres in special patient groups, including older adults and patients with Type 2 Diabetes, where studies assessed outcomes linked to markers of kidney function. Data for pediatric patients are still emerging, and research is ongoing with modest sample sizes.


What is Still Uncertain About the Research

The broader evidence landscape contributes to understanding symptom patterns, but several research limitations exist. Comparative evidence is lacking in some areas, and certainty remains low for outcomes related to all-cause mortality across all heart failure presentations when the agent is used in certain combinations. Results apply only to the populations studied, and findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Candepres (FAQ)


Q: Is Candepres a beta-blocker or an ACE inhibitor, or something else entirely?

A: Candepres is classified as an Angiotensin II Receptor Blocker (ARB). According to official product information, it works by selectively blocking the action of a hormone called Angiotensin II. This mechanism is distinct from that of ACE inhibitors and beta-blockers, though it is also used to help manage cardiovascular conditions.


Q: Does Candepres interact badly with common pain relievers like ibuprofen?

A: Regulatory documents indicate that Candepres may interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes ibuprofen. This combination may reduce Candepres's blood pressure-lowering effect. There is also a potential increased risk of worsening kidney function, especially in people who are elderly or dehydrated.


Q: Is it normal to have mild headaches when first starting Candepres?

A: Headache is listed as a Common adverse reaction in the official product information. Regulatory labeling indicates this frequency of occurrence, but official information does not specify how long this effect may last.


Q: Does Candepres have a risk of causing swelling in the face or throat?

A: The official product information lists Angioedema as a rare adverse reaction. Angioedema is a type of swelling that can affect the face, lips, tongue, or throat. It is considered a serious reaction that has been reported with this class of medication.


Q: Can Candepres affect kidney function over the long term?

A: Deterioration of renal function or renal impairment is listed as a very rare but clinically significant reaction. Patients with pre-existing kidney conditions may require medical monitoring. The drug's mechanism of action influences fluid and electrolyte balance, which is managed by the kidneys.


Q: Can Candepres cause changes in my mood or feelings of depression?

A: Official labels list effects like dizziness and headache but do not typically list changes in mood or depression as common or very rare side effects. Concerns about mood should be discussed with a healthcare professional.


Q: What common over-the-counter cold medicines interact with Candepres?

A: The regulatory documents specifically caution about potential interactions with NSAIDs, which are ingredients in some over-the-counter cold remedies. Additionally, taking Candepres with any other medicine that lowers blood pressure may increase the risk of side effects like low blood pressure.


Q: Why is it important to take Candepres at the same time every day?

A: Candepres is formulated for once-daily intake. This consistent timing supports the maintenance of steady drug levels, which is intended to provide sustained support for blood pressure management across the dosing interval.


Q: Is it safe to drive or operate machinery after taking Candepres?

A: Caution is advised when driving or operating machinery. The official product information notes that the medicine can cause side effects like dizziness (a common reaction) and, less frequently, fatigue, which may affect alertness. Because of these potential effects, an individual should use caution when performing activities that require alertness.


Q: Can Candepres be crushed or split if it's hard to swallow?

A: According to the official prescribing information, Candepres tablets may be crushed to prepare an extemporaneous oral suspension for patients who are unable to swallow the tablet whole. This method is mentioned in the prescribing information as an option for patients unable to swallow the tablet whole. Instructions for splitting the tablet for routine use are not typically provided.


Q: Does Candepres interact with any alcohol consumption?

A: Regulatory information indicates that consuming alcohol may increase the risk of side effects like dizziness or fainting. This is due to the additive effects of both alcohol and the medication lowering blood pressure in the body.


Q: What happens to my blood pressure if I suddenly stop Candepres?

A: Candepres is generally intended for sustained, long-term use for chronic conditions. Stopping a medication used to manage blood pressure suddenly, particularly without consulting a healthcare professional, may result in the blood pressure rising and the loss of therapeutic control.


Q: What are the most common side effects people complain about when taking Candepres?

A: Official documents classify adverse reactions based on frequency reported in clinical trials, listing upper respiratory tract infection, dizziness, and headache as Common. Information on subjective patient complaints from public sources is not included in regulatory labeling.


Q: Will taking Candepres make me feel tired or dizzy during the day?

A: Official labeling lists dizziness as a common side effect of Candepres. However, tiredness or fatigue is typically not listed among the commonly reported adverse reactions. Since blood pressure can be affected, some individuals may still experience a feeling of low energy.


Q: Are there any specific foods or supplements I need to avoid with Candepres?

A: Official documents specifically warn about concurrent use of Potassium Supplements, Potassium-Sparing Agents, or Salt Substitutes containing potassium. This is due to the risk of increased potassium levels in the blood (hyperkalemia). Candepres can be taken with or without food.


Q: How long does Candepres stay in your system after you stop taking it?

A: The active substance, Candesartan, has a half-life of approximately 9 hours. The half-life is the time it takes for half of the drug to be eliminated from the body. It takes several half-lives for a medication to be fully cleared from the system.


Q: Why do some doctors prescribe Candepres for heart failure?

A: Candepres is officially indicated for the treatment of Chronic Heart Failure. Its mechanism of action helps block signals that promote structural changes, such as thickening, in the heart and blood vessels. This sustained action supports cardiovascular function over time.


Q: Is there a generic version of Candepres, and is it as effective?

A: The active ingredient, Candesartan cilexetil, is available as a generic product. Generic versions must meet rigorous bioequivalence standards set by government regulatory bodies. Meeting these standards means the generic is considered therapeutically equivalent to the brand-name product.


Q: Does Candepres help protect against stroke?

A: Candepres is indicated for the treatment of high blood pressure and heart failure. Successfully managing high blood pressure is broadly known to help reduce the risk of stroke. However, the official labeling focuses on the established indications, not explicitly on stroke prevention as a primary claim.


Q: Can Candepres make me feel thirsty or cause changes in urination?

A: While the drug’s mechanism affects fluid and electrolyte balance in the body, changes in thirst or urination are not typically listed among the common or very rare adverse reactions in the official labeling. Serious side effects may involve the renal/urinary system, which can sometimes impact these functions.


Q: Is it normal for my heart rate to change after starting Candepres?

A: The drug's primary action is on blood pressure, and very low blood pressure (hypotension) is a known serious reaction. However, changes in heart rate, such as a very fast or very slow pulse, are not commonly listed as routine side effects in the official product information.

How should Candepres be stored and disposed of?

How to Store and Dispose of Candesartan Cilexetil

Storage Conditions

Candesartan cilexetil tablets must be stored at Controlled Room Temperature, specifically ranging from 20 C to 25 C (68 F to 77 F). The medication requires protection from both light and moisture and must be kept in its original container in a dry place. As a mandatory safety measure, the tablets must always be stored out of the reach of children.

Disposal Instructions

Unused or expired product should be disposed of in accordance with local pharmaceutical waste regulations. The medicine must not be discarded into routine household trash or poured down a drain or toilet unless specifically advised by official local guidance. Utilize drug take-back programs, when available, for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Candepres found in:

A-Z Index: